TISIDB

Summary
Symbol	NLGN2
Name	neuroligin 2
Aliases	KIAA1366; Neuroligin-2
Chromosomal Location	17p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein Cell junction, synapse, postsynaptic cell membrane Cell junction, synapse, presynaptic cell membrane Note=Detected at postsynaptic membranes in brain. Detected at dendritic spines in cultured neurons. Colocalizes with GPHN and ARHGEF9 at neuronal cell membranes (By similarity). Localized at presynaptic membranes in retina. Colocalizes with GABRG2 at inhibitory synapses in the retina (By similarity).
Domain	PF00135 Carboxylesterase family
Function	Transmembrane scaffolding protein involved in cell-cell interactions via its interactions with neurexin family members. Mediates cell-cell interactions both in neurons and in other types of cells, such as Langerhans beta cells. Plays a role in synapse function and synaptic signal transmission, especially via gamma-aminobutyric acid receptors (GABA(A) receptors). Functions by recruiting and clustering synaptic proteins. Promotes clustering of postsynaptic GABRG2 and GPHN. Modulates signaling by inhibitory synapses, and thereby plays a role in controlling the ratio of signaling by excitatory and inhibitory synapses and information processing. Required for normal signal amplitude from inhibitory synapses, but is not essential for normal signal frequency. May promote the initial formation of synapses, but is not essential for this. In vitro, triggers the de novo formation of presynaptic structures. Mediates cell-cell interactions between Langerhans beta cells and modulates insulin secretion (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0001941 postsynaptic membrane organization GO:0002087 regulation of respiratory gaseous exchange by neurological system process GO:0002790 peptide secretion GO:0002791 regulation of peptide secretion GO:0002793 positive regulation of peptide secretion GO:0003016 respiratory system process GO:0007158 neuron cell-cell adhesion GO:0007215 glutamate receptor signaling pathway GO:0007270 neuron-neuron synaptic transmission GO:0007416 synapse assembly GO:0007585 respiratory gaseous exchange GO:0007626 locomotory behavior GO:0009306 protein secretion GO:0009914 hormone transport GO:0010469 regulation of receptor activity GO:0010817 regulation of hormone levels GO:0015833 peptide transport GO:0019233 sensory perception of pain GO:0022898 regulation of transmembrane transporter activity GO:0023061 signal release GO:0030072 peptide hormone secretion GO:0030073 insulin secretion GO:0032024 positive regulation of insulin secretion GO:0032228 regulation of synaptic transmission, GABAergic GO:0032230 positive regulation of synaptic transmission, GABAergic GO:0032409 regulation of transporter activity GO:0032412 regulation of ion transmembrane transporter activity GO:0034330 cell junction organization GO:0034331 cell junction maintenance GO:0034762 regulation of transmembrane transport GO:0034765 regulation of ion transmembrane transport GO:0035249 synaptic transmission, glutamatergic GO:0035418 protein localization to synapse GO:0035640 exploration behavior GO:0035641 locomotory exploration behavior GO:0042391 regulation of membrane potential GO:0042886 amide transport GO:0043576 regulation of respiratory gaseous exchange GO:0043954 cellular component maintenance GO:0044057 regulation of system process GO:0044065 regulation of respiratory system process GO:0044089 positive regulation of cellular component biogenesis GO:0044091 membrane biogenesis GO:0044708 single-organism behavior GO:0045216 cell-cell junction organization GO:0045217 cell-cell junction maintenance GO:0046879 hormone secretion GO:0046883 regulation of hormone secretion GO:0046887 positive regulation of hormone secretion GO:0050708 regulation of protein secretion GO:0050714 positive regulation of protein secretion GO:0050796 regulation of insulin secretion GO:0050803 regulation of synapse structure or activity GO:0050804 modulation of synaptic transmission GO:0050806 positive regulation of synaptic transmission GO:0050807 regulation of synapse organization GO:0050808 synapse organization GO:0050885 neuromuscular process controlling balance GO:0050905 neuromuscular process GO:0051047 positive regulation of secretion GO:0051222 positive regulation of protein transport GO:0051640 organelle localization GO:0051648 vesicle localization GO:0051932 synaptic transmission, GABAergic GO:0051962 positive regulation of nervous system development GO:0051963 regulation of synapse assembly GO:0051965 positive regulation of synapse assembly GO:0051966 regulation of synaptic transmission, glutamatergic GO:0051968 positive regulation of synaptic transmission, glutamatergic GO:0060078 regulation of postsynaptic membrane potential GO:0060079 excitatory postsynaptic potential GO:0060080 inhibitory postsynaptic potential GO:0071709 membrane assembly GO:0072553 terminal button organization GO:0072657 protein localization to membrane GO:0090087 regulation of peptide transport GO:0090276 regulation of peptide hormone secretion GO:0090277 positive regulation of peptide hormone secretion GO:0097090 presynaptic membrane organization GO:0097091 synaptic vesicle clustering GO:0097104 postsynaptic membrane assembly GO:0097105 presynaptic membrane assembly GO:0097106 postsynaptic density organization GO:0097107 postsynaptic density assembly GO:0097116 gephyrin clustering involved in postsynaptic density assembly GO:0097119 postsynaptic density protein 95 clustering GO:0097151 positive regulation of inhibitory postsynaptic potential GO:0097479 synaptic vesicle localization GO:0098815 modulation of excitatory postsynaptic potential GO:0098828 modulation of inhibitory postsynaptic potential GO:0099054 presynapse assembly GO:0099068 postsynapse assembly GO:0099504 synaptic vesicle cycle GO:0099565 chemical synaptic transmission, postsynaptic GO:0099601 regulation of neurotransmitter receptor activity GO:1900449 regulation of glutamate receptor signaling pathway GO:1902473 regulation of protein localization to synapse GO:1902474 positive regulation of protein localization to synapse GO:1903532 positive regulation of secretion by cell GO:1904861 excitatory synapse assembly GO:1904862 inhibitory synapse assembly GO:1904951 positive regulation of establishment of protein localization GO:2000311 regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity GO:2000463 positive regulation of excitatory postsynaptic potential GO:2000807 regulation of synaptic vesicle clustering GO:2000809 positive regulation of synaptic vesicle clustering
Molecular Function	GO:0042043 neurexin family protein binding GO:0050839 cell adhesion molecule binding GO:0052689 carboxylic ester hydrolase activity
Cellular Component	GO:0042734 presynaptic membrane GO:0045211 postsynaptic membrane GO:0060077 inhibitory synapse GO:0097060 synaptic membrane GO:0098793 presynapse GO:0098794 postsynapse

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04514 Cell adhesion molecules (CAMs)
Reactome	R-HSA-6794361: Interactions of neurexins and neuroligins at synapses R-HSA-112316: Neuronal System R-HSA-6794362: Protein-protein interactions at synapses

Summary
Symbol	NLGN2
Name	neuroligin 2
Aliases	KIAA1366; Neuroligin-2
Chromosomal Location	17p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NLGN2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	NLGN2
Name	neuroligin 2
Aliases	KIAA1366; Neuroligin-2
Chromosomal Location	17p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NLGN2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NLGN2
Name	neuroligin 2
Aliases	KIAA1366; Neuroligin-2
Chromosomal Location	17p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NLGN2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.78	0.0497
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.845	0.199
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.002	0.999
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.092	0.822
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.341	0.865
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.212	0.94
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.041	0.917
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.098	0.94
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.093	0.945
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.804	0.456
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.188	0.424
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.038	0.749

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NLGN2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	0	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	0	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	NLGN2
Name	neuroligin 2
Aliases	KIAA1366; Neuroligin-2
Chromosomal Location	17p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NLGN2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NLGN2
Name	neuroligin 2
Aliases	KIAA1366; Neuroligin-2
Chromosomal Location	17p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NLGN2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NLGN2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NLGN2
Name	neuroligin 2
Aliases	KIAA1366; Neuroligin-2
Chromosomal Location	17p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NLGN2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NLGN2
Name	neuroligin 2
Aliases	KIAA1366; Neuroligin-2
Chromosomal Location	17p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NLGN2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NLGN2
Name	neuroligin 2
Aliases	KIAA1366; Neuroligin-2
Chromosomal Location	17p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NLGN2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NLGN2
Name	neuroligin 2
Aliases	KIAA1366; Neuroligin-2
Chromosomal Location	17p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NLGN2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse NLGN2